We are live on ! Find out more
TTNP

Titan Pharmaceuticals
TTNP

Delisted

TTNP was delisted on the 1st of October, 2025.

Back to rankings

15 hedge funds and large institutions have $2.65M invested in Titan Pharmaceuticals in 2016 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 4 increasing their positions, 1 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

2,186% more call options, than puts

Call options by funds: $1.35M | Put options by funds: $59K

300% more repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 1

38% less funds holding

Funds holding: 24 → 15 (-9)

67% less capital invested

Capital invested by funds: $8.07M → $2.65M (-$5.42M)

90% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 10

Holders
15
Holders Change
-9
Holders Change %
-37.5%
% of All Funds
0.4%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
4
Reduced
1
Closed
10
Calls
$1.35M
Puts
$59K
Net Calls
+$1.29M
Net Calls Change
+$1.28M

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$1M
2
DADC
D.A. Davidson & Co
Montana
+$147K
3
SIM
Spark Investment Management
New York
+$66.7K
4
Bank of New York Mellon
Bank of New York Mellon
New York
+$53.4K
5
Northern Trust
Northern Trust
Illinois
+$40K

Top Sellers

Rank Fund Capital Flow
1
BC
Broadfin Capital
New York
-$3.38M
2
PA
Perceptive Advisors
New York
-$1.94M
3
Millennium Management
Millennium Management
New York
-$277K
4
Renaissance Technologies
Renaissance Technologies
New York
-$275K
5
VKH
Virtu KCG Holdings
New York
-$225K
Name Holding Trade Value Shares
Change 		Change in
Stake
Goldman Sachs
26
Goldman Sachs
New York
– -$48K -3 Closed
TRCT
27
Tower Research Capital (TRC)
New York
– -$19K -1 Closed
VIA
28
Vantage Investment Advisors
Pennsylvania
– -$10K -1 Closed
HNB
29
Huntington National Bank
Ohio
– -$2K – –
1
2

TTNP Hedge Fund Activity: Q1 2016 in Review

15 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in Titan Pharmaceuticals (TTNP) for Q1 2016, worth a combined $2.65M — down 67% from $8.07M a quarter earlier.

Sellers outnumbered buyers: 10 funds closed out of TTNP and 1 opened new positions — a net loss of 9 holders — while 1 trimmed existing stakes and 4 added.

The largest buyer was Vanguard Group, adding an estimated $1M. The largest seller was Broadfin Capital, exiting entirely with an estimated $3.38M sold.

  • 15 institutional investors held Titan Pharmaceuticals (TTNP) as of Q1 2016, down from 24 in Q4 2015.
  • Funds reported $2.65M of Titan Pharmaceuticals stock for Q1 2016, down 67% quarter-over-quarter.
  • 1 fund opened new Titan Pharmaceuticals positions in Q1 2016 and 10 closed out, a net change of -9 holders.
  • The largest Titan Pharmaceuticals buyer in Q1 2016 was Vanguard Group, an estimated $1M added.
  • The largest Titan Pharmaceuticals seller in Q1 2016 was Broadfin Capital, an estimated $3.38M sold.

Based on aggregated 13F filings for Q1 2016.